Livzon Pharmaceutical (000513) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 2.87 billion, down 9.73% year-over-year due to lower incidence of respiratory diseases and policy impacts.

• Net profit attributable to shareholders was RMB 577 million, a 9.39% decrease year-over-year.

• Core business quality remained resilient despite industry policy transitions and seasonal fluctuations.

• Company is accelerating innovative product launches, expanding R&D pipeline, and deepening internationalization.

Financial highlights

• Operating cash flow increased 12.8% year-over-year to RMB 817 million.

• Basic and diluted EPS were both RMB 0.65, down 8.45% year-over-year.

• Total assets at period end were RMB 24.19 billion, up 0.87% from year-end 2025.

• Shareholders’ equity rose 4.47% from year-end 2025 to RMB 14.51 billion.

Outlook and guidance

• Innovative drugs included in the national reimbursement list are expected to drive future growth.

• Late-stage R&D products are moving toward commercialization, supporting mid- to long-term development.

• International expansion, including the Vietnam IMP acquisition, is progressing as planned.